Indications -- obesity/erectile dysfunction Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- obesity/erectile dysfunction

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (103)	4/29/2003 4:38:17 PM
From: Icebrg	Read Replies (1) of 435

Neurocrine Biosciences Reports First Quarter 2003 Results Tuesday April 29, 4:31 pm ET The Company Also Announces the Inlicensing of a Phase II Compound From Pharmacia (Now Pfizer) for Erectile Dysfunction Comments: Their newfounds friends at Pfizer are very helpful, although this was not what I thought they had in mind when they started to talk about inlicensing. The good thing is that is a seemingly advanced product. The bad thing is that the market (if they make it so far) will be very competetive. It would be interesting to know what competetive advantages this product may have. Another me-too Viagra type of pill will not cut it. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next